THE MARKET LEADING INNOVATOR OF BIOPHYSICAL TECHNIQUES TO SUPPORT MODERN DRUG DISCOVERY
In its 13 years of existence, ZoBio has integrated modern drug discovery technologies into an efficient pipeline to support hit to lead programs on targets that no other CRO can address.
Starting with our proprietary Target Immobilized NMR Screening (TINS) technology, which has been used in over 70 projects, ZoBio delivers highly validated fragment ligands for a wide array of challenging targets. We are developing industry leading, innovative techniques to support FBDD, including novel NMR methods to rapidly elucidate the structure of target – ligand complexes. Computational chemistry methods are integrated with our exclusive NMR techniques to steer hit-to-lead optimization and enable rapid progression of fragment hits into potent and ligand-efficient lead compounds.
Combined with our in-house protein production, orthogonal validation methods, such as SPR & biochemical assays and direct access to exclusive synthetic chemistry, ZoBio possesses all the tools to support Fragment Based Drug Discovery programs, from gene to lead.